PURPOSE: To examine ovarian reserve following chemotherapy in women with Hodgkin's disease. METHODS: The study included nine patients who underwent ovarian tissue cryopreservation (OTCP) prior to chemotherapy consisting of the ABVD regimen (Adriamycin, bleomycin, vinblastine, and dacarbazine) and co-treatment with gonadotropin-releasing hormone agonist (GnRH-a) (Group A), and 13 patients treated by the ABVD protocol only without GnRH-a (Group B). The average age was 25.2 +/- 2.7 years for the women in Group A and 31.8 +/- 6.8 years for those in Group B. RESULTS: Six months following the end of chemotherapy, the menstrual cycle resumed in all Group A patients and in four Group B patients who had amenorrhea. Eight Group B patients had regular menses during and after chemotherapy. None of the patients suffered from ovarian failure. Two Group A patients conceived in the first year after completing chemotherapy. CONCLUSIONS: Co-treatment with GnRH-a has little effect on ovarian protection in women with Hodgkin's disease.
PURPOSE: To examine ovarian reserve following chemotherapy in women with Hodgkin's disease. METHODS: The study included nine patients who underwent ovarian tissue cryopreservation (OTCP) prior to chemotherapy consisting of the ABVD regimen (Adriamycin, bleomycin, vinblastine, and dacarbazine) and co-treatment with gonadotropin-releasing hormone agonist (GnRH-a) (Group A), and 13 patients treated by the ABVD protocol only without GnRH-a (Group B). The average age was 25.2 +/- 2.7 years for the women in Group A and 31.8 +/- 6.8 years for those in Group B. RESULTS: Six months following the end of chemotherapy, the menstrual cycle resumed in all Group A patients and in four Group B patients who had amenorrhea. Eight Group B patients had regular menses during and after chemotherapy. None of the patients suffered from ovarian failure. Two Group A patients conceived in the first year after completing chemotherapy. CONCLUSIONS: Co-treatment with GnRH-a has little effect on ovarian protection in women with Hodgkin's disease.
Authors: I A J van Rooij; F J M Broekmans; E R te Velde; B C J M Fauser; L F J M M Bancsi; F H de Jong; A P N Themmen Journal: Hum Reprod Date: 2002-12 Impact factor: 6.918
Authors: B Pereyra Pacheco; J M Méndez Ribas; G Milone; I Fernández; R Kvicala; T Mila; A Di Noto; O Contreras Ortiz; S Pavlovsky Journal: Gynecol Oncol Date: 2001-06 Impact factor: 5.482
Authors: J H Waxman; R Ahmed; D Smith; P F Wrigley; W Gregory; S Shalet; D Crowther; L H Rees; G M Besser; J S Malpas Journal: Cancer Chemother Pharmacol Date: 1987 Impact factor: 3.333
Authors: Foad Azem; Israel Yovel; Israel Wagman; Rita Kapostiansky; Joseph B Lessing; Ami Amit Journal: Fertil Steril Date: 2003-05 Impact factor: 7.329
Authors: G P Canellos; J R Anderson; K J Propert; N Nissen; M R Cooper; E S Henderson; M R Green; A Gottlieb; B A Peterson Journal: N Engl J Med Date: 1992-11-19 Impact factor: 91.245